The critical role of chemokine (C-C motif) receptor 2-positive monocytes in autoimmune cholangitis

Debby Reuveni, Yael Gore, Patrick S Leung, Yael Lichter, Itay Moshkovits, Ayelet Kaminitz, Eli Brazowski, Eric Lefebvre, Pamela Vig, Chen Varol, Zamir Halpern, Oren Shibolet, M. Eric Gershwin, Ehud Zigmond

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The therapy of primary biliary cholangitis (PBC) has lagged behind other autoimmune diseases despite significant improvements in our understanding of both immunological and molecular events that lead to loss of tolerance to the E2 component of pyruvate dehydrogenase, the immunodominant autoepitope of PBC. It is well known that Ly6Chi monocytes are innate immune cells infiltrating inflammatory sites that are dependent on the expression of C-C motif chemokine receptor 2 (CCR2) for emigration from bone marrow. Importantly, humans with PBC have a circulating monocyte pro-inflammatory phenotype with macrophage accumulation in portal tracts. We have taken advantage of an inducible chemical xenobiotic model of PBC and recapitulated the massive infiltration of monocytes to portal areas. To determine the clinical significance, we immunized both CCR2-deficient mice and controls with 2OA-BSA and noted that CCR2 deficiency is protective for the development of autoimmune cholangitis. Importantly, because of the therapeutic potential, we focused on inhibiting monocyte infiltration through the use of cenicriviroc (CVC), a dual chemokine receptor CCR2/CCR5 antagonist shown to be safe in human trials. Importantly, treatment with CVC resulted in amelioration of all aspects of disease severity including serum total bile acids, histological severity score, and fibrosis stage. In conclusion, our results indicate a major role for Ly6Chi monocytes and for CCR2 in PBC pathogenesis and suggest that inhibition of this axis by CVC should be explored in humans through the use of clinical trials.

Original languageEnglish (US)
Article number1852
JournalFrontiers in Immunology
Volume9
Issue numberAUG
DOIs
StatePublished - Aug 15 2018

Fingerprint

CCR Receptors
Cholangitis
C Chemokines
Chemokine Receptors
Monocytes
Chemical Models
Emigration and Immigration
Xenobiotics
Bile Acids and Salts
Pyruvic Acid
Autoimmune Diseases
Oxidoreductases
Fibrosis
Bone Marrow
Macrophages
Clinical Trials
Phenotype
Therapeutics
Serum

Keywords

  • Chemokine
  • Macrophages
  • Monocytes
  • Primary biliary cholangitis
  • Therapy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

The critical role of chemokine (C-C motif) receptor 2-positive monocytes in autoimmune cholangitis. / Reuveni, Debby; Gore, Yael; Leung, Patrick S; Lichter, Yael; Moshkovits, Itay; Kaminitz, Ayelet; Brazowski, Eli; Lefebvre, Eric; Vig, Pamela; Varol, Chen; Halpern, Zamir; Shibolet, Oren; Gershwin, M. Eric; Zigmond, Ehud.

In: Frontiers in Immunology, Vol. 9, No. AUG, 1852, 15.08.2018.

Research output: Contribution to journalArticle

Reuveni, D, Gore, Y, Leung, PS, Lichter, Y, Moshkovits, I, Kaminitz, A, Brazowski, E, Lefebvre, E, Vig, P, Varol, C, Halpern, Z, Shibolet, O, Gershwin, ME & Zigmond, E 2018, 'The critical role of chemokine (C-C motif) receptor 2-positive monocytes in autoimmune cholangitis', Frontiers in Immunology, vol. 9, no. AUG, 1852. https://doi.org/10.3389/fimmu.2018.01852
Reuveni, Debby ; Gore, Yael ; Leung, Patrick S ; Lichter, Yael ; Moshkovits, Itay ; Kaminitz, Ayelet ; Brazowski, Eli ; Lefebvre, Eric ; Vig, Pamela ; Varol, Chen ; Halpern, Zamir ; Shibolet, Oren ; Gershwin, M. Eric ; Zigmond, Ehud. / The critical role of chemokine (C-C motif) receptor 2-positive monocytes in autoimmune cholangitis. In: Frontiers in Immunology. 2018 ; Vol. 9, No. AUG.
@article{cdb3fd912c174970a1ba36ce11904f83,
title = "The critical role of chemokine (C-C motif) receptor 2-positive monocytes in autoimmune cholangitis",
abstract = "The therapy of primary biliary cholangitis (PBC) has lagged behind other autoimmune diseases despite significant improvements in our understanding of both immunological and molecular events that lead to loss of tolerance to the E2 component of pyruvate dehydrogenase, the immunodominant autoepitope of PBC. It is well known that Ly6Chi monocytes are innate immune cells infiltrating inflammatory sites that are dependent on the expression of C-C motif chemokine receptor 2 (CCR2) for emigration from bone marrow. Importantly, humans with PBC have a circulating monocyte pro-inflammatory phenotype with macrophage accumulation in portal tracts. We have taken advantage of an inducible chemical xenobiotic model of PBC and recapitulated the massive infiltration of monocytes to portal areas. To determine the clinical significance, we immunized both CCR2-deficient mice and controls with 2OA-BSA and noted that CCR2 deficiency is protective for the development of autoimmune cholangitis. Importantly, because of the therapeutic potential, we focused on inhibiting monocyte infiltration through the use of cenicriviroc (CVC), a dual chemokine receptor CCR2/CCR5 antagonist shown to be safe in human trials. Importantly, treatment with CVC resulted in amelioration of all aspects of disease severity including serum total bile acids, histological severity score, and fibrosis stage. In conclusion, our results indicate a major role for Ly6Chi monocytes and for CCR2 in PBC pathogenesis and suggest that inhibition of this axis by CVC should be explored in humans through the use of clinical trials.",
keywords = "Chemokine, Macrophages, Monocytes, Primary biliary cholangitis, Therapy",
author = "Debby Reuveni and Yael Gore and Leung, {Patrick S} and Yael Lichter and Itay Moshkovits and Ayelet Kaminitz and Eli Brazowski and Eric Lefebvre and Pamela Vig and Chen Varol and Zamir Halpern and Oren Shibolet and Gershwin, {M. Eric} and Ehud Zigmond",
year = "2018",
month = "8",
day = "15",
doi = "10.3389/fimmu.2018.01852",
language = "English (US)",
volume = "9",
journal = "Frontiers in Immunology",
issn = "1664-3224",
publisher = "Frontiers Media S. A.",
number = "AUG",

}

TY - JOUR

T1 - The critical role of chemokine (C-C motif) receptor 2-positive monocytes in autoimmune cholangitis

AU - Reuveni, Debby

AU - Gore, Yael

AU - Leung, Patrick S

AU - Lichter, Yael

AU - Moshkovits, Itay

AU - Kaminitz, Ayelet

AU - Brazowski, Eli

AU - Lefebvre, Eric

AU - Vig, Pamela

AU - Varol, Chen

AU - Halpern, Zamir

AU - Shibolet, Oren

AU - Gershwin, M. Eric

AU - Zigmond, Ehud

PY - 2018/8/15

Y1 - 2018/8/15

N2 - The therapy of primary biliary cholangitis (PBC) has lagged behind other autoimmune diseases despite significant improvements in our understanding of both immunological and molecular events that lead to loss of tolerance to the E2 component of pyruvate dehydrogenase, the immunodominant autoepitope of PBC. It is well known that Ly6Chi monocytes are innate immune cells infiltrating inflammatory sites that are dependent on the expression of C-C motif chemokine receptor 2 (CCR2) for emigration from bone marrow. Importantly, humans with PBC have a circulating monocyte pro-inflammatory phenotype with macrophage accumulation in portal tracts. We have taken advantage of an inducible chemical xenobiotic model of PBC and recapitulated the massive infiltration of monocytes to portal areas. To determine the clinical significance, we immunized both CCR2-deficient mice and controls with 2OA-BSA and noted that CCR2 deficiency is protective for the development of autoimmune cholangitis. Importantly, because of the therapeutic potential, we focused on inhibiting monocyte infiltration through the use of cenicriviroc (CVC), a dual chemokine receptor CCR2/CCR5 antagonist shown to be safe in human trials. Importantly, treatment with CVC resulted in amelioration of all aspects of disease severity including serum total bile acids, histological severity score, and fibrosis stage. In conclusion, our results indicate a major role for Ly6Chi monocytes and for CCR2 in PBC pathogenesis and suggest that inhibition of this axis by CVC should be explored in humans through the use of clinical trials.

AB - The therapy of primary biliary cholangitis (PBC) has lagged behind other autoimmune diseases despite significant improvements in our understanding of both immunological and molecular events that lead to loss of tolerance to the E2 component of pyruvate dehydrogenase, the immunodominant autoepitope of PBC. It is well known that Ly6Chi monocytes are innate immune cells infiltrating inflammatory sites that are dependent on the expression of C-C motif chemokine receptor 2 (CCR2) for emigration from bone marrow. Importantly, humans with PBC have a circulating monocyte pro-inflammatory phenotype with macrophage accumulation in portal tracts. We have taken advantage of an inducible chemical xenobiotic model of PBC and recapitulated the massive infiltration of monocytes to portal areas. To determine the clinical significance, we immunized both CCR2-deficient mice and controls with 2OA-BSA and noted that CCR2 deficiency is protective for the development of autoimmune cholangitis. Importantly, because of the therapeutic potential, we focused on inhibiting monocyte infiltration through the use of cenicriviroc (CVC), a dual chemokine receptor CCR2/CCR5 antagonist shown to be safe in human trials. Importantly, treatment with CVC resulted in amelioration of all aspects of disease severity including serum total bile acids, histological severity score, and fibrosis stage. In conclusion, our results indicate a major role for Ly6Chi monocytes and for CCR2 in PBC pathogenesis and suggest that inhibition of this axis by CVC should be explored in humans through the use of clinical trials.

KW - Chemokine

KW - Macrophages

KW - Monocytes

KW - Primary biliary cholangitis

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=85051639436&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051639436&partnerID=8YFLogxK

U2 - 10.3389/fimmu.2018.01852

DO - 10.3389/fimmu.2018.01852

M3 - Article

C2 - 30158929

AN - SCOPUS:85051639436

VL - 9

JO - Frontiers in Immunology

JF - Frontiers in Immunology

SN - 1664-3224

IS - AUG

M1 - 1852

ER -